Market closed

Intra-Cellular Therapies/$ITCI

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Intra-Cellular Therapies

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Ticker

$ITCI
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
New York, United States

Employees

610
Website
www.intracellulartherapies.com

ITCI Metrics

BasicAdvanced
$13B
-
-$0.86
1.00
-

$13B

1

$128.00

$62.78

2.3M

7.656

6.936

1.18

1.547

-7.44%

-9.90%

20.815

11.75

11.75

-203.061

46.08%

-47.18%

105.63%

-35.52%

What the Analysts think about ITCI

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Intra-Cellular Therapies stock.

ITCI Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ITCI Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

ITCI News

AllArticlesVideos
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

Business Wire·2 days ago
Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders

Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders

Business Wire·2 days ago
Drugmakers rush to sign deals on first day of industry conference

Drugmakers rush to sign deals on first day of industry conference

Reuters·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ITCI

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Intra-Cellular Therapies stock?

Intra-Cellular Therapies (ITCI) has a market cap of $13B as of January 15, 2025.

What is the P/E ratio for Intra-Cellular Therapies stock?

The price to earnings (P/E) ratio for Intra-Cellular Therapies (ITCI) stock is 0 as of January 15, 2025.

Does Intra-Cellular Therapies stock pay dividends?

No, Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Intra-Cellular Therapies dividend payment date?

Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders.

What is the beta indicator for Intra-Cellular Therapies?

Intra-Cellular Therapies (ITCI) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.